title: Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects: a review of randomized studies.
abstract: Migraine might be associated with high blood pressure (BP), which can cause more severe and more difficult to treat forms of headache. To evaluate the efficacy of frovatriptan and other triptans in the acute treatment of migraine, in patients classified according to a history of arterial hypertension, enrolled in three randomized, double-blind, crossover, Italian studies. Migraineurs with or without aura were randomized to frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). After treating up to three episodes of migraine in 3 months with the first treatment, patients switched to the alternate treatment for the next 3 months. The present analysis assessed triptan efficacy in 60 subjects with a history of treated or untreated essential arterial hypertension (HT) and in 286 normotensive (NT) subjects. During the study, migraine attacks with aura were significantly more prevalent in HT subjects (21 vs. 13 % NT, p < 0.001). The proportion of pain free at 2 h did not significantly differ between HTs and NTs for either frovatriptan (25 vs. 26 %) or the comparators (33 vs. 32 %). Pain relief was achieved in significantly (p < 0.05) fewer episodes in HT subjects for both frovatriptan (41 vs. 52 % NT) and the comparators (48 vs. 58 %). Relapses at 48 h were similarly low in HTs and NTs with frovatriptan (29 vs. 31 %), while they were significantly (p < 0.05) larger in HTs (62 %) than in NTs (44 %) with comparators. No BP or heart rate increment was observed during the study in HT subjects. No difference in tolerability was reported between HTs and NTs. In conclusion, HT individuals tend to be less responsive than NT migraineurs to triptan therapy. However, frovatriptan, in contrast to other triptans, seems to have a sustained antimigraine effect in both HT and NT patients.
authors.affiliation: Department of Clinical Neuroscience, Headache Unit, C. Besta Neurological Institute and Foundation, Milan, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Tullo
authors.forename: G
authors.initials: G
authors.lastname: Bussone
authors.forename: S
authors.initials: S
authors.lastname: Omboni
authors.forename: P
authors.initials: P
authors.lastname: Barbanti
authors.forename: P
authors.initials: P
authors.lastname: Cortelli
authors.forename: M
authors.initials: M
authors.lastname: Curone
authors.forename: C
authors.initials: C
authors.lastname: Peccarisi
authors.forename: C
authors.initials: C
authors.lastname: Benedetto
authors.forename: D
authors.initials: D
authors.lastname: Pezzola
authors.forename: D
authors.initials: D
authors.lastname: Zava
authors.forename: G
authors.initials: G
authors.lastname: Allais
mesh_terms: D002227:Carbazoles / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000150:complications*; D008881:Migraine Disorders / Q000188:drug therapy* / Q000209:etiology; D023303:Oxazolidinones / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use; D014363:Tryptamines / Q000627:therapeutic use*
chemical_list: D002227:Carbazoles; D023303:Oxazolidinones; D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C409045:almotriptan; C089750:zolmitriptan; C093622:rizatriptan; C108128:frovatriptan